Cytotoxicity Screening for Future Evaluation of Tranexamic Acid and its Derivatives for Rapid Hemorrhage Control and Patient Stabilization in Combat

Traumatic hemorrhage is the leading cause of preventable combat deaths, with limited resources in austere environments. Tranexamic and valproic acid have shown promise in improving coagulopathy and survival. This study explores different cell toxicity assays to evaluate the relationship with small molecules like tranexamic acid (TXA) and valproic acid (VPA). TXA exhibited dose-dependent cytotoxicity, with A549 cells resilient, while VPA showed heightened toxicity across all cell lines. These findings highlight the need for safer hemostatic agents, with TXA derivatives as a potential solution for combat hemorrhage control.